Daiichi Sankyo

AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug
Pharmaceutical Business Review
Mon, 05/11/20 - 10:27 am
AstraZeneca
Daiichi Sankyo
FDA
Enhertu
gastric cancer
breakthrough therapy
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Tue, 03/31/20 - 11:05 am
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer
Fierce Biotech
Wed, 03/25/20 - 10:49 am
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
HER2-positive non-small cell lung cancer
AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
Fierce Pharma
Mon, 02/10/20 - 11:42 pm
AstraZeneca
Daiichi Sankyo
clinical trials
FDA
Enhertu
cancer
breast cancer
Antibody-drug conjugates on the march
Pharmaforum
Thu, 01/30/20 - 10:41 am
antibody-drug conjugate
AstraZeneca
Daiichi Sankyo
Enhertu
Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study
Endpoints
Mon, 01/27/20 - 10:44 am
AstraZeneca
breast cancer
Daiichi Sankyo
trastuzumab deruxtecan
gastric cancer
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing
Pharmaforum
Mon, 12/23/19 - 11:46 pm
FDA
AstraZeneca
Daiichi Sankyo
advanced breast cancer
Enhertu
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
BioPharma Dive
Fri, 12/20/19 - 08:19 pm
Daiichi Sankyo
AstraZeneca
FDA
drug approvals
breast cancer
trastuzumab deruxtecan
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
EP Vantage
Wed, 12/11/19 - 10:24 am
breast cancer
AstraZeneca
Daiichi Sankyo
SABCS
trastuzumab deruxtecan
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
BioSpace
Tue, 12/3/19 - 10:29 pm
Seattle Genetics
Daiichi Sankyo
antibody-drug conjugate
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Endpoints
Fri, 11/8/19 - 10:40 am
Daiichi Sankyo
Exelixis
clinical trials
diabetic nephropathy
Minnebro
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Pharmaforum
Wed, 11/6/19 - 10:18 am
Daiichi Sankyo
Seattle Genetics
breast cancer
AstraZeneca
trastuzumab deruxtecan
Herceptin
Daiichi sues Seattle Genetics over tech used in high-profile ADC
Fierce Biotech
Tue, 11/5/19 - 10:34 am
Daiichi Sankyo
Seattle Genetics
antibody-drug conjugate
AstraZeneca
DS-8201
Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny
Fierce Pharma
Mon, 11/4/19 - 07:27 pm
Daiichi Sankyo
oncology
painkillers
opioids
opioid crisis
Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute
Pharmaceutical Business Review
Fri, 11/1/19 - 10:35 am
Daiichi Sankyo
Sarah Cannon Research Institute
antibody-drug conjugate
DS-7300
clinical trials
solid tumors
Recent Job Cuts in the Biopharma Industry
BioSpace
Mon, 10/7/19 - 11:29 pm
Tocagen
Sanofi
Amneal
Daiichi Sankyo
Integra Life Sciences
Aclaris
Bayer
Novartis
Illumina
Merck
Roche Molecular Systems
Prometheus Labs
layoffs
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Pharmaforum
Sun, 09/22/19 - 11:02 pm
Astellas
AML
Xospata
Europe
Daiichi Sankyo
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Endpoints
Fri, 09/20/19 - 10:40 pm
Astellas
FDA
gilteritinib
Europe
AML
Daiichi Sankyo
Daiichi Sankyo to cut 69 opioid sales jobs
Beckers Hospital Review
Tue, 08/13/19 - 10:26 am
Daiichi Sankyo
opioids
layoffs
drug reps
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Endpoints
Mon, 08/5/19 - 11:32 am
Daiichi Sankyo
FDA
pexidartinib
Turalio
tenosynovial giant cell tumors

Pages